#Oncoalert

Nicole Kuderer

NicoleKuderer

@US_FDA Fantastic discussion of Pfizer/BioNtech vaccince - listen in :1) Possible that social distancing contributed some to great efficacy data in the intervention arm.2) Reverse transcript data unavailable. But Limited

Stephen V Liu

StephenVLiu

#WCLC20 The plenary presentation by @GoldmanLisa on patient-directed research and lessons in partnership is a can't miss and gives important insight into the evolution of clinical research #LCSM @IASLC @OncoAlert

Benedikt Westphalen

BenWestphalen

0/6 Background: Liquid biopsies have the potential to become an invaluable tool in the management of #cancer. That’s why, it is important to generate solid evidence to define areas in

Vivek Subbiah, MD

VivekSubbiah

1/6Molecular Profiling of Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes published as Rapid impact paper @oalhalabimd et al @MCR_AACR @AACR @CancerMedMDA #GU21 @ASCO @OncoAlert #bcsm https://bit.ly/3d25A1U

Stephen V Liu

StephenVLiu

#OncoAlert Available @NEJM, results from the phase III CROWN trial of lorlatinib versus crizotinib as first line treatment for #ALK NSCLC. Initially presented at virtual #ESMO20, lorlatinib had a significantly

Vivek Subbiah, MD

VivekSubbiah

1/10 COVID19 & CancerSeveral studies now provide insights into the enigma surrounding the determinants of COVID-19 & cancer A global effort to understand the riddles of COVID-19 and cancer @NatureCancer

Eugene Pietzak

eugene_pietzak

@TheWonkologist: All great & valid points, IMHO we as a #bladdercancer community are just so desperate for an alternative to cystectomy & @FDAOncology already set the bar so low with

Stephen V Liu

StephenVLiu

#OncoAlert Retrospective report @JTOonline on outcomes with chemoradiation plus durvalumab (PACIFIC) in patients with #EGFR mutant NSCLC. #LCSM https://www.jto.org/article/S1556-0864(21)01702-0/fulltext Cohort of 37 patients with #EGFR muta

Stephen V Liu

StephenVLiu

#OncoAlert Results from the phase III TAHOE trial now available @JTOonline - compared 2L rovalpituzumab-teserine (Rova-T) versus topotecan in DLL3-high #SCLC. Stopped early for futility, not meeting its OS endpoint.

Jonathan Marron MD MPH

JonMarronMD

Out now: Our paper on "State Government Crisis Standards of Care Guidelines: Implications for Patients with Cancer" https://ja.ma/3oqa2tO via @JAMAOnc of @JAMANetwork Kudos to our @DanaFarber @DanaFarberNews team for their

Pashtoon Kasi MD, MS

pashtoonkasi

Another agnostic approval.#Pembrolizumab #TMBTMB cutoff >=Though I’m overall very supportive of agnostic approvals overall, not sure if TMB is the same across tissue types. @US_FDA #OncoAlert #PrecisionMedicine https://seekingalpha.com

Vivek Subbiah, MD

VivekSubbiah

By popular demand The Top 10 clinical publications in Oncology in 2020 (In no particular order). Some important papers bundled + Additional 5 more papers representing major advances in the

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.